New combo aims to halt early blood cancer before it worsens
NCT ID NCT03516617
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two drugs, acalabrutinib and obinutuzumab, can eliminate signs of cancer in patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma who are at high risk of progression. About 120 participants will be randomly assigned to receive either acalabrutinib alone or both drugs together. The goal is to see if the combination leads to deeper remission and delays the need for further treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib and obinutuzumab
What this could lead to
If successful, this could offer a way to achieve deep remission in early-stage CLL/SLL, potentially delaying the need for more intensive treatment.
What could go wrong
This is a phase 2 trial with only 120 participants, so results are preliminary. The drugs may cause side effects like infections or bleeding, and not all patients may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic in Florida
ACTIVE_NOT_RECRUITINGJacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact